about
Recent advances in the management of hemodialysis patients: a focus on cardiovascular diseaseVascular calcification in end-stage renal diseaseAging and vascular endothelial function in humansEndoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.Assessment of vascular function in patients with chronic kidney disease.25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adultsAging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humansRenal outcomes and dietary potassium: the overshadowed electrolyte?Effect of dietary sodium restriction on human urinary metabolomic profiles.Vascular endothelial function is not related to serum uric acid in healthy adults.25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population.Tetrahydrobiopterin supplementation enhances carotid artery compliance in healthy older men: a pilot study.Regular aerobic exercise protects against impaired fasting plasma glucose-associated vascular endothelial dysfunction with aging.Dietary sodium restriction reverses vascular endothelial dysfunction in middle-aged/older adults with moderately elevated systolic blood pressure.Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humansVascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthaseDietary sodium restriction and association with urinary marinobufagenin, blood pressure, and aortic stiffness.Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults.A guiding map for inflammation.Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease.Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.Posthemodialysis weights and mortality: another narrow range target?Chronic kidney disease: Cystatin-C-based eGFR: what is it telling us?High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men.Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial.Dietary Sodium/Potassium Intake Does Not Affect Cognitive Function or Brain Imaging Indices.IL-1 Inhibition and Vascular Function in CKD.Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.Frequent hemodialysis: a way to improve physical function?Serum Sodium and Cognition in Older Community-Dwelling Men.Strategies for Achieving Healthy Vascular Aging.Vascular Function and Uric Acid-Lowering in Stage 3 CKD.Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over StudyVascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney DiseaseInterleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical functionShould statin therapy be expanded in patients with CKD?Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic PotentialIL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKDAffected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study
P50
Q26849298-DCB5A73C-8D2C-453E-8A82-5A33FC947ADDQ27009551-630F0BAB-21D4-4C96-8822-128B9445AD22Q28390251-7DFF5631-7A3D-4B2D-9B1D-561086F03629Q30618674-47928575-CF32-4191-B65D-BD17B1FA5009Q34323504-595753E7-D945-49C3-9211-C44757020E53Q34485935-1B35B624-0F4E-460C-9BB3-391BD040FF9FQ34545820-AE465D4A-9DAE-43C3-8048-52550CA3C2A8Q34581556-5BA600CB-D5AD-485D-B139-CD964F7C3765Q35817074-7E223266-ECAF-44F8-95FF-540909A240D2Q35843077-3C51B442-2946-4E8F-8B32-44F3A5620E92Q35949312-1D96D74D-38CC-46DD-A937-8D5B1915B8FBQ36352929-9C160362-5959-4270-8772-A8ADC853B095Q36433519-28C1EBE0-9D01-493E-B6DF-8958228EE211Q36545354-C23D2975-DED4-4A72-926F-7077132F59AAQ36956466-6BE5A74B-DEBA-4636-9D21-D72BDF2A2DF0Q37264432-EB02779F-FDC3-46BD-B1C2-800F8915AD11Q37280786-63D477F4-279C-4B46-AC3B-CCA3CA3E6B9BQ38758897-B05976A9-3507-4071-B4A9-CD247CA4D073Q38998962-A3665236-BDD9-451E-AB28-070211AD6672Q40128384-80AB9B9D-00E0-426C-88BC-039EED4E0D22Q41097666-9E8D6DDE-578E-4255-9008-5648E2618BECQ41823915-DFB35F21-6854-4249-AEF8-5C8C222B5E6DQ42569064-04B36188-C344-4350-8106-C27753D8D390Q44821800-42E40F21-F0A5-43D3-98DD-AD97F5EB369BQ46927709-E887B776-162B-4255-A638-CA9EAFCD07A7Q47302709-F64F08A1-6260-43A0-8859-554078F8F43AQ47549567-43D25C97-41FD-4397-ABE7-E6EB5903469BQ48040831-123DB42F-CFE6-4C3B-8CF3-647047DB0F55Q48339739-7ECFDF5E-89EF-4BF3-BBDC-DD2495875D1EQ48453499-5F74A1D8-7D4B-40A1-A6C1-EEF0815EF6B9Q50035777-2AB354E0-FC7F-475E-8982-74097A06C600Q50133565-4529C3E2-43DF-4574-BB9C-CD7F207C9646Q55077663-DE5BB131-0B1D-44E1-9339-E7F65935D376Q57293904-877C373A-E6AB-45C5-8992-5C15F1CCA754Q57293919-98733405-81B8-4E34-B6A6-787AC5483CD6Q62271292-CE61FFE9-C7FB-4E70-AA47-5C3A21A5B375Q62271332-2CF674C3-AED4-4765-9930-F7D60C952652Q89837577-9EB3863D-E2E3-4F3B-9AEB-60269CDB3F96Q90250474-B16E41F9-076A-4D69-B1E1-112F10983A4FQ95413886-AE1FEF5C-D8D0-4B6C-8DD8-0581DDCB5894
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kristen L Nowak
@ast
Kristen L Nowak
@en
Kristen L Nowak
@es
Kristen L Nowak
@nl
Kristen L Nowak
@sl
type
label
Kristen L Nowak
@ast
Kristen L Nowak
@en
Kristen L Nowak
@es
Kristen L Nowak
@nl
Kristen L Nowak
@sl
altLabel
Kristen Jablonski
@en
Kristen L Jablonski
@en
Kristen Nowak
@en
prefLabel
Kristen L Nowak
@ast
Kristen L Nowak
@en
Kristen L Nowak
@es
Kristen L Nowak
@nl
Kristen L Nowak
@sl
P108
P106
P21
P31
P496
0000-0001-9364-3256